Papillary renal cell carcinoma
MONDO:0017884A rare subtype of renal cell carcinoma, arising from the renal tubular epithelium and showing a papillary growth pattern, which typically manifests with hematuria, flank pain, palpable abdominal mass or nonspecific symptoms, such as fatigue, weight loss or fever. Symptoms related to metastatic spread, such as bone pain or persistent cough, are frequently associated since early diagnosis is not common. It is typically multifocal, bilateral, and in most cases sporadic, although different hereditary syndromes, such as Hereditary leiomyoma renal cell carcinoma, Birt-Hogg-DubC) syndrome and Tuberous sclerosis, may predispose to the development of papillary renal cell carcinoma.
Also known as: HPRCC, chromophil carcinoma of kidney, chromophil carcinoma of the kidney, chromophil renal cell carcinoma, papillary (chromophil) renal cell carcinoma, papillary renal cell adenocarcinoma, papillary renal cell cancer, papillary renal cell carcinoma
2794 clinical trials for this condition and its sub-types, 25 tagged with Papillary renal cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Papillary renal cell carcinoma
-
New combo aims to outsmart Hard-to-Treat kidney cancer
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib helps people with advanced papillary kidney cancer live longer without their disease getting worse. About 200 participants will receive either cabozantinib alone or cabo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Promising combo aims to ease bone pain in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise for rare kidney cancers
Disease control OngoingThis study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the com…
Phase 2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Head-to-Head drug battle for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
Disease control OngoingThis phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for rare kidney cancer: drug combo shows promise in late-stage trial
Disease control OngoingThis phase 3 study tests whether combining two drugs (savolitinib and durvalumab) works better than the standard drug sunitinib for people with a rare, advanced kidney cancer called papillary renal cell carcinoma that has a specific genetic change (MET-driven). About 148 adults w…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo shows promise for rare kidney cancers
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …
Phase 1/2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Gut bacteria booster may help kidney cancer drugs work better
Disease control OngoingThis early-phase trial is testing whether adding a probiotic called CBM588 to the standard combination of cabozantinib and nivolumab can improve treatment for advanced or metastatic kidney cancer. The probiotic is designed to restore helpful gut bacteria that may help the immune …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo shows promise for tough kidney cancers
Disease control OngoingThis study tests two drugs, nivolumab and cabozantinib, together in 60 people with advanced or metastatic non-clear cell kidney cancer. The goal is to see how well the combination shrinks tumors. Participants take cabozantinib daily and receive nivolumab infusions every two weeks…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can AI be a Pathologist's second opinion?
Diagnosis By invitation onlyThis trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their ow…
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC